Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy

Asian Journal of Andrology

Volumn 15, Issue 1, 2013, Pages 110-115

  Qu, Yuan Yuan ^a,b   Dai, Bo ^a,b   Kong, Yun Yi ^a,b   Ye, Ding Wei ^a,b   Yao, Xu Dong ^a,b   Zhang, Shi Lin ^a,b   Zhang, Hai Liang ^a,b   Ma, Chun Guang ^a,b   Yang, Wei Yi ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

castration resistant; docetaxel; metastatic; overall survival; prognostic factor; prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; DOCETAXEL; HEMOGLOBIN; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CASTRATION RESISTANT PROSTATE CANCER; CHINESE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHINA; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORCHIECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS;

EID: 84872192734     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2012.110     Document Type: Article

References (20)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-92. (Pubitemid 46359643)
2. Dai B, Ye DW, Kong YY, Shen YJ, Wang BH. Individualized prostate biopsy strategy for Chinese patients with different prostate-Specific antigen levels. Asian J Androl 2008; 10: 325-31. (Pubitemid 351337998)
3. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24. (Pubitemid 19211484)
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20. (Pubitemid 39315318)
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A et al. Docetaxel and prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12. (Pubitemid 39315317)
6. Petrylak DP. The treatment of hormone-refractory prostate cancer: Docetaxel and beyond. Rev Urol 2006; 8(SUPPL2): 48-55.
7. He J, Zeng ZC, Yang P, Chen B, JiangWet al. Clinical features and prognostic factors for patients with bone metastases from prostate cancer. Asian J Androl 2012; 14: 505-8.
8. Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ . Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 2010; e-Pub ahead of print 29 Sep 2010; doi:10.1016/j.urolonc. 2010.07.002.
9. Saad F, Segal S, Eastham J. Prostate-Specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid. Eur Urol 2012; e-Pub ahead of print 12 May 2012; doi:10.1016/j.eururo.2012.05.007.
10. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clin Cancer Res 2007; 13: 6396-403. (Pubitemid 350075029)
11. Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M et al. Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival. Anticancer Res 2011; 31: 1475-82.
12. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-9.
13. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011; 71: 6019-29.
14. Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, NanusDMet al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 2012; 61: 549-59.
15. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7. (Pubitemid 29211767)
16. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-Specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Onocol 2002; 20: 4567-73. (Pubitemid 35402960)
17. Teeter AE, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ et al. Does PSADT after radical prostatectomy correlate with overall survival? - A report from the SEARCH database group. Urology 2011; 77: 149-53.
18. Cook RJ, Coleman R, Brown J, Lipton A, Major P et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006; 12: 3361-7.
19. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20: 3972-82.
20. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-7. (Pubitemid 46606398)